Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: POLBF )

0.1180 UNCHANGED
Last Price Updated: 3:19 PM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about POLBF

< Previous 1 2 3 Next >
Poolbeg Pharma PLC Announces Interim Results for the Six Months to 30 June 2023
Via ACCESSWIRE
Poolbeg Pharma and CytoReason identify "very exciting influenza targets"
Poolbeg Pharma and CytoReason identify "very exciting influenza targets" 
Via News Direct
Topics Artificial Intelligence
Exposures Artificial Intelligence
Poolbeg Pharma and CytoReason identify "very exciting influenza targets"
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington and CytoReason co-founder and CEO David Harel speak to Thomas Warner from Proactive after announcing what they call a "significant... 
Via TheNewswire.com
Topics Artificial Intelligence
Exposures Artificial Intelligence
Poolbeg Pharma PLC Announces AI Led Programme Identifies Influenza Drug Targets
Via ACCESSWIRE
Poolbeg Pharma PLC - Oral Vaccine Programme Moves Forward
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Annual Report & AGM Notice
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2022
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Strategic Expansion of POLB 001 into Oncology
Via ACCESSWIRE
Poolbeg Pharma sees "significant commercial opportunity" in oral vaccines
Poolbeg Pharma sees "significant commercial opportunity" in oral vaccines 
Via News Direct
Poolbeg Pharma sees "significant commercial opportunity" in oral vaccines
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing that work on the company's Oral Vaccine Programme collaboration is now set to... 
Via TheNewswire.com
Poolbeg Pharma PLC Announces Board Appointment
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Results of Annual General Meeting
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Positive Initial Data Analysis in POLB 001 Trial
Via ACCESSWIRE
Poolbeg Identifies Novel RSV Drug Candidates
Via ACCESSWIRE
Poolbeg Pharma PLC Announces Metabolic Diseases Oral Delivery Licence Signed
Via ACCESSWIRE
Poolbeg Pharma PLC - POLB 001 LPS Human Challenge Trial Completed
Via ACCESSWIRE
Poolbeg Pharma "in a very healthy cash position" after first full year of operations
Poolbeg Pharma "in a very healthy cash position" after first full year of operations 
Via News Direct
Poolbeg Pharma "in a very healthy cash position" after first full year of operations
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after publishing final results for 2022 that show that the clinical-stage biotech company finished its first full... 
Via TheNewswire.com
Proactive's Robin Davison publishes fresh research note on Poolbeg Pharma
Proactive's Robin Davison publishes fresh research note on Poolbeg Pharma 
Via News Direct
Proactive's Robin Davison publishes fresh research note on Poolbeg Pharma
Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new report on Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), following the release of selected data from its human... 
Via TheNewswire.com
Poolbeg Pharma "couldn't be happier" with POLB 001 human challenge trial data
Poolbeg Pharma "couldn't be happier" with POLB 001 human challenge trial data 
Via News Direct
Poolbeg Pharma PLC Announces Influenza AI model build completed
Via ACCESSWIRE
Poolbeg Pharma "couldn't be happier" with POLB 001 human challenge trial data
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive's Thomas Warner after announcing the data readout from an LPS human challenge trial for POLB 001, the infectious... 
Via TheNewswire.com
Poolbeg Pharma "really open" to different types of deal for POLB 001
Poolbeg Pharma "really open" to different types of deal for POLB 001 
Via News Direct
Poolbeg Pharma "really open" to different types of deal for POLB 001
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) VP of Business Development David English speaks to Proactive's Thomas Warner about the work he's doing to progress the clinical stage infectious disease... 
Via TheNewswire.com
Poolbeg Pharma announces expansion of POLB 001 into oncology
Poolbeg Pharma announces expansion of POLB 001 into oncology 
Via News Direct
Topics Intellectual Property
Exposures Intellectual Property
Poolbeg Pharma announces expansion of POLB 001 into oncology
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive's Thomas Warner after announcing that the company has submitted a patent application for the use of POLB 001 in a... 
Via TheNewswire.com
Topics Intellectual Property
Exposures Intellectual Property
Poolbeg Pharma upbeat on preliminary influenza drug results
Poolbeg Pharma upbeat on preliminary influenza drug results 
Via News Direct
Poolbeg Pharma upbeat on preliminary influenza drug results
Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential... 
Via TheNewswire.com
Poolbeg Pharma PLC Announces Capital Markets Day
Via ACCESSWIRE
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.